Analysis of intravitreal injections at the State Public Servant Hospital of São Paulo

Abstract Objective: The objective of this work was to generate information about the profile of the patients submitted to Intravitreal Injections (IVIs) and also to evaluate the indications and costs of the procedure. Methods: The study was carried out with own protocols, applied through the analysis of medical records of patients submitted to IVIs at the State Public Servant Hospital of São Paulo from January 2017 to June 2018. Data were analyzed in the form of descriptive study. Results: The results showed that 3181 injections were performed in 1421 eyes in the study period; the main drug injected was Bevacizumab; the main pathology treated was Diabetic Maculopathy; and the cost with these procedures was at least R$ 776,257.56. Most diabetic patients did not have adequate glycemic control. Many patients with AMD had no documented improvement in Visual Acuity. Conclusion: It was concluded that deep analyzes about the indications of IVIs should be performed for the benefit of public servants of São Paulo. The information generated by this study can be used to improve the service through the development of therapeutic protocols, as well as serving as a starting point for new research and actions related to the topic.

摘要
研究目的：本研究旨在明确接受玻璃体内注射（Intravitreal Injections, IVIs）患者的临床特征，并评估该操作的适应证与相关成本。
研究方法：本研究采用自研方案，对2017年1月至2018年6月期间，圣保罗州公立公务员医院收治的接受玻璃体内注射患者的医疗记录进行回顾性分析，属于描述性研究范畴。
研究结果：本次研究周期内共计完成3181次注射，涉及1421只患眼；主要注射药物为贝伐珠单抗（Bevacizumab）；主要治疗的眼底病理类型为糖尿病性黄斑病变（Diabetic Maculopathy）；该类操作的总成本至少为776257.56雷亚尔（R$）。多数糖尿病患者未实现良好的血糖控制，许多年龄相关性黄斑变性（Age-related Macular Degeneration, AMD）患者未出现有记录的视力改善。
研究结论：本研究认为，应针对玻璃体内注射的适应证开展深入分析，以惠及圣保罗州的公务员群体。本研究生成的相关数据可用于优化诊疗方案的制定，进而提升医疗服务质量，同时亦可作为该领域后续研究与相关行动的参考起点。